Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.prabhatkhabar.com/news/celebrity/swara-bhaskar-had-to-speak-out-against-the-caa-and-nrc-people-made-hug
Are you over 18 and want to see adult content?
A complete backup of www.indiatoday.in/movies/bollywood/story/shubh-mangal-zyada-saavdhan-movie-review-ayushmann-khurrana-and-ji
Are you over 18 and want to see adult content?
A complete backup of www.prabhatkhabar.com/news/celebrity/swara-bhaskar-had-to-speak-out-against-the-caa-and-nrc-people-made-hug
Are you over 18 and want to see adult content?
A complete backup of nos.nl/l/2323884
Are you over 18 and want to see adult content?
A complete backup of us.as.com/us/2020/02/23/futbol/1582412667_750324.html
Are you over 18 and want to see adult content?
Favourite Annotations
İnstagram Takipçi Hilesi - İnstagram Beğeni | instabayim
Are you over 18 and want to see adult content?
ایمیل های جالب | بیایید آنقدر از خوبی ها بگوییم تا... جایی برای بدی نماند.
Are you over 18 and want to see adult content?
Group Buy SEO Tools - SEO Group Buy 100% Up- Frozenfry
Are you over 18 and want to see adult content?
Nisargadatta Maharaj - Message, Quotes and 'I am That'
Are you over 18 and want to see adult content?
New Homes For Sale On The Nansemond River In Suffolk, VA
Are you over 18 and want to see adult content?
Get Visibility of Network Traffic, Users and Security
Are you over 18 and want to see adult content?
Mindzai Toy Shop - Designer Toys and Creative Goods
Are you over 18 and want to see adult content?
Text
Dermatomyositis.
OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative PUBLICATIONS & PRESENTATIONS : CORBUS PHARMACEUTICALS Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Company Overview. Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit theendocannabinoid
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
JOB OPPORTUNITIES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. There is no place for politics or red tape here. CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) DERMATOMYOSITIS :: CORBUS PHARMACEUTICALS HOLDINGS, INC Dermatomyositis. Dermatomyositis (DM), a form of myositis, is a chronic, rare, life-threatening, inflammatory, systemic autoimmune disease affecting approximately 80,000 people in the U.S., EU and Japan. 1 The signs and symptoms of DM reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also include pulmonary, cardiac HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Recent News. 04/20/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) 03/30/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment ofDermatomyositis.
OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative PUBLICATIONS & PRESENTATIONS : CORBUS PHARMACEUTICALS Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
PRESS RELEASES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021. March 8, 2021. OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Company Overview. Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit theendocannabinoid
PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis JOB OPPORTUNITIES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. There is no place for politics or red tape here. ABOUT CORBUS PHARMACEUTICALS HOLDINGS : CORBUS Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory strategies and operations to support the drug development process. PIPELINE :: CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
MEET OUR EMPLOYEES : CORBUS PHARMACEUTICALS HOLDINGS, INC. We are committed to providing every employee with the resources and skills to succeed. Meet some of our employees to learn more about their roles, their experiences and what makes working at Corbus so rewarding.”. Brendan Hart. Senior Compliance Specialist, Clinical Quality Assurance. We care about cultivating a work environment thatsupports
PARTNERING : CORBUS PHARMACEUTICALS HOLDINGS, INC. Partnering. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. We understand the importance of collaborations in our industry, and our Business Development team is always focused on potential new opportunities. ENDOCANNABINOID SYSTEM SCIENCE : CORBUS PHARMACEUTICALS Lenabasum. Corbus’ most advanced compound lenabasum is an oral, small molecule that selectively activates CB2. Biologic activities of lenabasum have been shown in animal models and humans, and include activation of the resolution of inflammation, reducing BOARD OF DIRECTORS : CORBUS PHARMACEUTICALS HOLDINGS, INC. Pete Salzmann, M.D., MBA. Director. Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member of its board of directors since October 2019. FINANCIALS : CORBUS PHARMACEUTICALS HOLDINGS, INC. Warrants and options that have not been exercised have been excluded from the diluted calculation as all periods presented have a net loss and the impact of these securities would be anti-dilutive ANNUAL REPORTS : CORBUS PHARMACEUTICALS HOLDINGS, INC. 170. 03/08/17. 10-K. Annual report pursuant to Section 13 and 15 (d) Related Documents. EX-23.1. EX-31.1. NIH-SPONSORED PHASE 2 STUDY IN SYSTEMIC LUPUS NIH-Sponsored Phase 2 Study in Systemic Lupus Erythematosus (SLE) This study is sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative Network. HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Recent News. 04/20/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) 03/30/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment ofDermatomyositis.
OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative PUBLICATIONS & PRESENTATIONS : CORBUS PHARMACEUTICALS Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Company Overview. Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit theendocannabinoid
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
JOB OPPORTUNITIES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. There is no place for politics or red tape here. CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) DERMATOMYOSITIS :: CORBUS PHARMACEUTICALS HOLDINGS, INC Dermatomyositis. Dermatomyositis (DM), a form of myositis, is a chronic, rare, life-threatening, inflammatory, systemic autoimmune disease affecting approximately 80,000 people in the U.S., EU and Japan. 1 The signs and symptoms of DM reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also include pulmonary, cardiac HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Recent News. 04/20/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) 03/30/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment ofDermatomyositis.
OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative PUBLICATIONS & PRESENTATIONS : CORBUS PHARMACEUTICALS Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Company Overview. Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit theendocannabinoid
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
JOB OPPORTUNITIES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. There is no place for politics or red tape here. CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) DERMATOMYOSITIS :: CORBUS PHARMACEUTICALS HOLDINGS, INC Dermatomyositis. Dermatomyositis (DM), a form of myositis, is a chronic, rare, life-threatening, inflammatory, systemic autoimmune disease affecting approximately 80,000 people in the U.S., EU and Japan. 1 The signs and symptoms of DM reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also include pulmonary, cardiac ABOUT CORBUS PHARMACEUTICALS HOLDINGS : CORBUS Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory strategies and operations to support the drug development process. PIPELINE :: CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
MEET OUR EMPLOYEES : CORBUS PHARMACEUTICALS HOLDINGS, INC. We are committed to providing every employee with the resources and skills to succeed. Meet some of our employees to learn more about their roles, their experiences and what makes working at Corbus so rewarding.”. Brendan Hart. Senior Compliance Specialist, Clinical Quality Assurance. We care about cultivating a work environment thatsupports
PARTNERING : CORBUS PHARMACEUTICALS HOLDINGS, INC. Partnering. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. We understand the importance of collaborations in our industry, and our Business Development team is always focused on potential new opportunities. ENDOCANNABINOID SYSTEM SCIENCE : CORBUS PHARMACEUTICALS Lenabasum. Corbus’ most advanced compound lenabasum is an oral, small molecule that selectively activates CB2. Biologic activities of lenabasum have been shown in animal models and humans, and include activation of the resolution of inflammation, reducing BOARD OF DIRECTORS : CORBUS PHARMACEUTICALS HOLDINGS, INC. Pete Salzmann, M.D., MBA. Director. Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member of its board of directors since October 2019. FINANCIALS : CORBUS PHARMACEUTICALS HOLDINGS, INC. Warrants and options that have not been exercised have been excluded from the diluted calculation as all periods presented have a net loss and the impact of these securities would be anti-dilutive ANNUAL REPORTS : CORBUS PHARMACEUTICALS HOLDINGS, INC. 170. 03/08/17. 10-K. Annual report pursuant to Section 13 and 15 (d) Related Documents. EX-23.1. EX-31.1. NIH-SPONSORED PHASE 2 STUDY IN SYSTEMIC LUPUS NIH-Sponsored Phase 2 Study in Systemic Lupus Erythematosus (SLE) This study is sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative Network. HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Recent News. 04/20/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) 03/30/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment ofDermatomyositis.
OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative PUBLICATIONS & PRESENTATIONS : CORBUS PHARMACEUTICALS Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Company Overview. Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit theendocannabinoid
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
JOB OPPORTUNITIES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. There is no place for politics or red tape here. CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) DERMATOMYOSITIS :: CORBUS PHARMACEUTICALS HOLDINGS, INC Dermatomyositis. Dermatomyositis (DM), a form of myositis, is a chronic, rare, life-threatening, inflammatory, systemic autoimmune disease affecting approximately 80,000 people in the U.S., EU and Japan. 1 The signs and symptoms of DM reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also include pulmonary, cardiac HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Recent News. 04/20/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) 03/30/2021 • 8:05 AM EDT. Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment ofDermatomyositis.
OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative PUBLICATIONS & PRESENTATIONS : CORBUS PHARMACEUTICALS Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Company Overview. Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit theendocannabinoid
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
JOB OPPORTUNITIES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. There is no place for politics or red tape here. CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) DERMATOMYOSITIS :: CORBUS PHARMACEUTICALS HOLDINGS, INC Dermatomyositis. Dermatomyositis (DM), a form of myositis, is a chronic, rare, life-threatening, inflammatory, systemic autoimmune disease affecting approximately 80,000 people in the U.S., EU and Japan. 1 The signs and symptoms of DM reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also include pulmonary, cardiac ABOUT CORBUS PHARMACEUTICALS HOLDINGS : CORBUS Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Ross Lobell joined Corbus as Vice President, Regulatory Affairs in April 2018. Mr. Lobell is an expert in regulatory affairs with an extensive biopharmaceutical background in leading preclinical, clinical and nonclinical regulatory strategies and operations to support the drug development process. PIPELINE :: CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
MEET OUR EMPLOYEES : CORBUS PHARMACEUTICALS HOLDINGS, INC. We are committed to providing every employee with the resources and skills to succeed. Meet some of our employees to learn more about their roles, their experiences and what makes working at Corbus so rewarding.”. Brendan Hart. Senior Compliance Specialist, Clinical Quality Assurance. We care about cultivating a work environment thatsupports
PARTNERING : CORBUS PHARMACEUTICALS HOLDINGS, INC. Partnering. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. We understand the importance of collaborations in our industry, and our Business Development team is always focused on potential new opportunities. ENDOCANNABINOID SYSTEM SCIENCE : CORBUS PHARMACEUTICALS Lenabasum. Corbus’ most advanced compound lenabasum is an oral, small molecule that selectively activates CB2. Biologic activities of lenabasum have been shown in animal models and humans, and include activation of the resolution of inflammation, reducing BOARD OF DIRECTORS : CORBUS PHARMACEUTICALS HOLDINGS, INC. Pete Salzmann, M.D., MBA. Director. Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member of its board of directors since October 2019. FINANCIALS : CORBUS PHARMACEUTICALS HOLDINGS, INC. Warrants and options that have not been exercised have been excluded from the diluted calculation as all periods presented have a net loss and the impact of these securities would be anti-dilutive ANNUAL REPORTS : CORBUS PHARMACEUTICALS HOLDINGS, INC. 170. 03/08/17. 10-K. Annual report pursuant to Section 13 and 15 (d) Related Documents. EX-23.1. EX-31.1. NIH-SPONSORED PHASE 2 STUDY IN SYSTEMIC LUPUS NIH-Sponsored Phase 2 Study in Systemic Lupus Erythematosus (SLE) This study is sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative Network. HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress. 05/19/2021 • 9:20 AM EDT. Corbus Pharmaceuticals Announces Adjournment of Annual Meeting. OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to CONTACT US : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals, Inc. 500 River Ridge Drive Norwood, MA 02062. Phone: 617.963.0100 Email: info@corbuspharma.com Investor Relations.Ted Jenkins, Senior
OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis DERMATOMYOSITIS :: CORBUS PHARMACEUTICALS HOLDINGS, INC Dermatomyositis. Dermatomyositis (DM), a form of myositis, is a chronic, rare, life-threatening, inflammatory, systemic autoimmune disease affecting approximately 80,000 people in the U.S., EU and Japan. 1 The signs and symptoms of DM reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also include pulmonary, cardiac JOB OPPORTUNITIES :: CORBUS PHARMACEUTICALS HOLDINGS, INC Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress. 05/19/2021 • 9:20 AM EDT. Corbus Pharmaceuticals Announces Adjournment of Annual Meeting. OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to CONTACT US : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals, Inc. 500 River Ridge Drive Norwood, MA 02062. Phone: 617.963.0100 Email: info@corbuspharma.com Investor Relations.Ted Jenkins, Senior
OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INC Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis DERMATOMYOSITIS :: CORBUS PHARMACEUTICALS HOLDINGS, INC Dermatomyositis. Dermatomyositis (DM), a form of myositis, is a chronic, rare, life-threatening, inflammatory, systemic autoimmune disease affecting approximately 80,000 people in the U.S., EU and Japan. 1 The signs and symptoms of DM reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also include pulmonary, cardiac JOB OPPORTUNITIES :: CORBUS PHARMACEUTICALS HOLDINGS, INC Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. ABOUT CORBUS PHARMACEUTICALS HOLDINGS : CORBUS Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative CONTACT US : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals, Inc. 500 River Ridge Drive Norwood, MA 02062. Phone: 617.963.0100 Email: info@corbuspharma.com Investor Relations.Ted Jenkins, Senior
PRESS RELEASES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021. March 8, 2021. PIPELINE :: CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized by chronic inflammation, fibrosis (for example, scarring RESOURCES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Resources. Dermatomyositis. Dermatomyositis, a form of myositis, is a chronic, rare, inflammatory, clinically heterogenous, life-threatening autoimmune disease affecting approximately 80,000 people in North America, EU and Japan. 1 The signs and symptoms of dermatomyositis reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle PRESENTATIONS : CORBUS PHARMACEUTICALS HOLDINGS, INC. 2021 Corbus Pharmaceuticals Holdings, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Contact Disclaimer Sitemap Contact PARTNERING : CORBUS PHARMACEUTICALS HOLDINGS, INC. Partnering. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. We understand the importance of collaborations in our industry, and our Business Development team is always focused on potential new opportunities. MEET OUR EMPLOYEES : CORBUS PHARMACEUTICALS HOLDINGS, INC. We are committed to providing every employee with the resources and skills to succeed. Meet some of our employees to learn more about their roles, their experiences and what makes working at Corbus so rewarding.”. Brendan Hart. Senior Compliance Specialist, Clinical Quality Assurance. We care about cultivating a work environment thatsupports
ENDOCANNABINOID SYSTEM SCIENCE : CORBUS PHARMACEUTICALS Lenabasum. Corbus’ most advanced compound lenabasum is an oral, small molecule that selectively activates CB2. Biologic activities of lenabasum have been shown in animal models and humans, and include activation of the resolution of inflammation, reducing NIH-SPONSORED PHASE 2 STUDY IN SYSTEMIC LUPUS NIH-Sponsored Phase 2 Study in Systemic Lupus Erythematosus (SLE) This study is sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative Network. HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress. 05/19/2021 • 9:20 AM EDT. Corbus Pharmaceuticals Announces Adjournment of Annual Meeting. OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative ABOUT CORBUS PHARMACEUTICALS HOLDINGS : CORBUS Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to CONTACT US : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals, Inc. 500 River Ridge Drive Norwood, MA 02062. Phone: 617.963.0100 Email: info@corbuspharma.com Investor Relations.Ted Jenkins, Senior
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INCCORBUS PHARMACEUTICAL HOLDINGS INCCORBUS PHARMACEUTICALS HOLDINGS INC NEWSCORBUS PHARMACEUTICALS ACCOUNTS PAYABLECORBUS PHARMACEUTICALS ANALYST FORECASTCORBUS PHARMACEUTICALS HQCORBUS PHARMACEUTICALS NEWSTODAY
Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
JOB OPPORTUNITIES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. There is no place for politics or red tape here. BOARD OF DIRECTORS : CORBUS PHARMACEUTICALS HOLDINGS, INC. Pete Salzmann, M.D., MBA. Director. Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member of its board of directors since October 2019. PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) HOME : CORBUS PHARMACEUTICALS HOLDINGS, INC.OUR COMPANYOUR SCIENCEFOR PHYSICIANSFOR PATIENTSFOR INVESTORSCAREERS Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress. 05/19/2021 • 9:20 AM EDT. Corbus Pharmaceuticals Announces Adjournment of Annual Meeting. OUR COMPANY : CORBUS PHARMACEUTICALS HOLDINGS, INC. Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative ABOUT CORBUS PHARMACEUTICALS HOLDINGS : CORBUS Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative OVERVIEW : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to CONTACT US : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals, Inc. 500 River Ridge Drive Norwood, MA 02062. Phone: 617.963.0100 Email: info@corbuspharma.com Investor Relations.Ted Jenkins, Senior
MANAGEMENT TEAM :: CORBUS PHARMACEUTICALS HOLDINGS, INCCORBUS PHARMACEUTICAL HOLDINGS INCCORBUS PHARMACEUTICALS HOLDINGS INC NEWSCORBUS PHARMACEUTICALS ACCOUNTS PAYABLECORBUS PHARMACEUTICALS ANALYST FORECASTCORBUS PHARMACEUTICALS HQCORBUS PHARMACEUTICALS NEWSTODAY
Chief Medical Officer and Head of Research. Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industryexperience in
OUR PIPELINE : CORBUS PHARMACEUTICALS HOLDINGS, INC. Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized bychronic
JOB OPPORTUNITIES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Culture. We are high achievers, creative, innovative and above all else, passionate about what we do. At Corbus, you will succeed based on your contribution and work ethic - not on your title or rank. There is no place for politics or red tape here. BOARD OF DIRECTORS : CORBUS PHARMACEUTICALS HOLDINGS, INC. Pete Salzmann, M.D., MBA. Director. Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member of its board of directors since October 2019. PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) ABOUT CORBUS PHARMACEUTICALS HOLDINGS : CORBUS Overview. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative CONTACT US : CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals, Inc. 500 River Ridge Drive Norwood, MA 02062. Phone: 617.963.0100 Email: info@corbuspharma.com Investor Relations.Ted Jenkins, Senior
PIPELINE :: CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Systemic Sclerosis. Systemic sclerosis (SSc), a form of scleroderma, is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S., EU and Japan. 1 SSc is more common in adults and women than in men and children, and typically occurs in people aged 30 to 50 years old. 2 The disease is characterized by chronic inflammation, fibrosis (for example, scarring RESOURCES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Resources. Dermatomyositis. Dermatomyositis, a form of myositis, is a chronic, rare, inflammatory, clinically heterogenous, life-threatening autoimmune disease affecting approximately 80,000 people in North America, EU and Japan. 1 The signs and symptoms of dermatomyositis reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle PHASE 3 DETERMINE STUDY IN DERMATOMYOSITIS : CORBUS Phase 3 DETERMINE Study in Dermatomyositis. Topline results from the study are on track to be reported in the second quarter of 2021. Study Details: Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176) ENDOCANNABINOID SYSTEM SCIENCE : CORBUS PHARMACEUTICALS Lenabasum. Corbus’ most advanced compound lenabasum is an oral, small molecule that selectively activates CB2. Biologic activities of lenabasum have been shown in animal models and humans, and include activation of the resolution of inflammation, reducing PARTNERING : CORBUS PHARMACEUTICALS HOLDINGS, INC. Partnering. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. We understand the importance of collaborations in our industry, and our Business Development team is always focused on potential new opportunities. PRESENTATIONS : CORBUS PHARMACEUTICALS HOLDINGS, INC. 2021 Corbus Pharmaceuticals Holdings, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Contact Disclaimer Sitemap Contact MEET OUR EMPLOYEES : CORBUS PHARMACEUTICALS HOLDINGS, INC. Meet Our Employees. “What I love about Corbus is that not only is there an opportunity to grow in the role you’re in, but there’s lots of opportunity to experience maybe a different role that you’re interest in that you might not get in a bigger company. You really get a full picture of the whole industry and how it works. NIH-SPONSORED PHASE 2 STUDY IN SYSTEMIC LUPUS NIH-Sponsored Phase 2 Study in Systemic Lupus Erythematosus (SLE) This study is sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative Network. Media Press Releases Contact Us* Home
* Our Company
* Leadership Team
* Board of Directors * Scientific Advisors* Partnering
* Our Pipeline
* Endocannabinoid System Science* Integrin Biology
* Publications & Presentations * Scientific Conferences* For Physicians
* Ongoing Clinical Trials * Grants and Charitable Giving* For Patients
* Advocacy at Corbus * Ongoing Clinical Trials * Grants and Charitable Giving* Resources
* For Investors
* Investor Relations* Overview
* Presentations
* Analyst Coverage
* News / Events
* Press Releases
* Events
* Email Alerts
* Company Info
* Profile
* Management Team
* IR Contacts
* FAQ
* Financial Info
* Financials
* Financial Results
* Stock Data
* Quote
* Charts
* Historical Data
* SEC Filings
* All SEC Filings
* Annual Reports
* Quarterly Reports
* Section 16 Filings* Governance
* Board of Directors* Board Committees
* Governance Docs
* Careers
* Job Opportunities
* Meet Our Employees* Culture
* Recruiting Scam Alert* Media
* Press Releases
* Contact Us
.slide" data-cycle-swipe="true" data-cycle-timeout="10000" data-cycle-log="false" data-cycle-pager="#cycle-pager" style="position: relative;"> CONNECTING INNOVATION TO PURPOSELatest News
Our Expanded Pipeline CONNECTING INNOVATION TO PURPOSELatest News
Our Expanded PipelineOUR COMMITMENT
We are committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer.Learn More
OUR SCIENCE
Corbus’ pipeline encompasses two different approaches to immunology: small molecules that activate or inhibit the body’s endocannabinoid system and monoclonal antibodies that target integrins to inhibit activation of TGFβ.Learn More
JOIN OUR TEAM
We are a unique team of individuals who are high-achieving, innovative, creative, and above all else, passionate about what we do.View Open Positions
View All News
RECENT NEWS
06/01/2021 • 7:05 AM EDT Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer andFibrotic Diseases
05/25/2021 • 8:05 AM EDT Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress INVESTOR INFORMATION VIEW INVESTOR RELATIONSCRBP
Nasdaq
Volume
Market Cap
Change
SIGN UP FOR EMAIL ALERTS Receive breaking news first.Learn More
INVESTOR PRESENTATION View our latest investor presentation.Download the pdf
2021 Corbus Pharmaceuticals Holdings, Inc. All rights reserved. Privacy Policy DisclaimerSitemap Contact
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0